MTX Response Assays Using PBMC ROS and Monocyte Metabolism

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack a biomarker to predict a patient's response to methotrexate treatment for rheumatoid arthritis before initiating therapy, leading to one-third of patients not responding adequately, which can result in joint destruction and sustained inflammatory activity.

Innovation Solution

Develops assays to measure reactive oxygen species (ROS) production and cellular metabolic activity in peripheral blood mononuclear cells (PBMCs) or monocytes, isolated from patients with rheumatoid arthritis, exposed to methotrexate in vitro, to predict clinical remission through increased ROS levels or reduced cellular metabolism, respectively.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If methotrexate is used as first-line treatment for rheumatoid arthritis, then treatment coverage is improved, but one third of patients do not respond adequately leading to joint destruction

Engineering Contradiction:

Improvetreatment response predictionVSAvoidjoint destruction

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by performing in vitro assays on patient cells before initiating methotrexate treatment to predict response. The method cultures peripheral blood mononuclear cells and exposes them to methotrexate, then measures cellular responses (ROS production, metabolic activity) in advance to determine whether the patient will respond to treatment, allowing clinicians to select appropriate patients before treatment begins.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses cellular intermediaries (peripheral blood mononuclear cells) as mediators to predict treatment response. These cells serve as an in vitro model that reflects in vivo response to methotrexate. By measuring metabolic activity and ROS production in these intermediary cells exposed to the drug, the method indirectly predicts clinical treatment outcomes without requiring trial-and-error in patients.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If no biomarker is available to predict MTX response, then treatment can be started without delay, but one third of patients will not respond adequately

Engineering Contradiction:

Improvetreatment initiation speedVSAvoidtreatment response

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The assay performs preliminary evaluation of treatment response potential before committing patients to long-term therapy. By culturing cells and measuring methotrexate effects in vitro (taking hours to days), the method provides predictive information in advance, allowing rapid patient selection without delaying overall treatment initiation for responsive patients.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent replaces the mechanical trial-and-error approach (starting treatment and waiting 6 months to assess response) with a biochemical in vitro testing system. Instead of mechanically observing clinical outcomes over months, the method uses cellular assays measuring metabolic activity and ROS production to substitute and predict the outcome, providing rapid response prediction.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Measurement precision

If in vitro assays are performed to measure ROS production and cellular metabolic activity, then prediction accuracy is improved with AUC values over 0.90, but assay complexity increases

Engineering Contradiction:

Improveresponse prediction accuracyVSAvoidassay complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent extracts specific measurable parameters (ROS production, cellular metabolic activity) from the complex biological system of drug response. By isolating and measuring these two key cellular responses in vitro, the method achieves high prediction accuracy (AUC > 0.90) while simplifying the assessment to quantifiable metrics that can be measured using standard laboratory techniques.

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The ROS and monocyte assays demonstrate high discriminatory power, with AUC values over 0.90 and 0.826, respectively, accurately predicting methotrexate response, enabling targeted treatment to prevent joint destruction.

Implementation Method 1

MTX is an anti-metabolite that possesses anti-proliferative and immunosuppressive activity by competitively inhibiting the enzyme dihydrofolate reductase, which catalyzes a key step in folic acid metabolism

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Implementation Method 2

Methodology Applied

Scientific EffectReactive oxygen species production: Oxidation

Data Source

PatentUS20250347692A1Method for determining the response to methotrexate (MTX) in a human subject diagnosed with rheumatoid arthritis

Publication Date: 2025.11.13 BIOHOPE SCI SOLUTIONS FOR HUMAN HEALTH SL

AI summary

The present invention relates to the medical field, specifically to the diagnostic/predictive field using biomarkers of response to methotrexate (MTX) in a human subject diagnosed with rheumatoid arthritis.